A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
← catalyst calendarNCT04077099 · readout in 2,073 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
231estimated
Sites
40
Countries
France, South Korea, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-07 | actual | When the study began enrolling |
| Primary completion | 2032-04-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-04-22 | estimated | The whole study's end, after follow-up |
| First posted | 2019-09-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NSCLC
Intervention
- Drug: REGN5093
Primary outcomes
what the primary-completion date above is the date OFNumber of patients with Dose Limiting Toxicities (DLTs)
measured Up to 21 days
Incidence and severity of treatment-emergent adverse events (TEAEs)
measured Through study completion, an average of 12 years
Incidence and severity of adverse events of special interest (AESIs)
measured Through study completion, an average of 12 years
Incidence and severity of serious adverse events (SAEs)
measured Through study completion, an average of 12 years
Incidence and severity of grade ≥3 laboratory abnormalities
measured Through study completion, an average of 12 years
REGN5093 concentrations in serum over time
measured Through study completion, an average of 12 years
Objective response rate (ORR) per RECIST 1.1
measured Through study completion, an average of 12 years
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed